Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer

Immune checkpoint inhibitors (ICI) are a novel medication for non-small cell lung cancer (NSCLC). Recent reports indicated that baseline tumor size (BTS) relates to the efficacy of ICI therapy for melanoma, but no study exists for NSCLC. This study aimed to evaluate the utility of BTS for ICI therap...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2019-02, Vol.39 (2), p.815-825
Main Authors: Katsurada, Masahiro, Nagano, Tatsuya, Tachihara, Motoko, Kiriu, Tatsunori, Furukawa, Koichi, Koyama, Kiyoko, Otoshi, Takehiro, Sekiya, Reina, Hazama, Daisuke, Tamura, Daisuke, Nakata, Kyosuke, Katsurada, Naoko, Yamamoto, Masatsugu, Kobayashi, Kazuyuki, Nishimura, Yoshihiro
Format: Article
Language:English
Subjects:
Aged
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents, Immunological - therapeutic use
Biomarkers, Tumor - metabolism
Cancer
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - immunology
Carcinoma, Non-Small-Cell Lung - pathology
Confidence intervals
Disease-Free Survival
Female
Humans
Immune checkpoint inhibitors
Kaplan-Meier Estimate
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - immunology
Lung Neoplasms - pathology
Male
Melanoma
Middle Aged
Nivolumab - therapeutic use
Non-small cell lung carcinoma
Prognosis
Retrospective Studies
Survival
Therapy
Treatment Outcome
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitors (ICI) are a novel medication for non-small cell lung cancer (NSCLC). Recent reports indicated that baseline tumor size (BTS) relates to the efficacy of ICI therapy for melanoma, but no study exists for NSCLC. This study aimed to evaluate the utility of BTS for ICI therapy. Data from 58 patients diagnosed with NSCLC who underwent ICI monotherapy, were retrospectively analyzed. Patients were divided into two groups according to BTS (below 101 mm, above 101 mm). The primary endpoint was progression-free survival (PFS) and the secondary endpoint was overall survival (OS). PFS of patients with a large BTS was significantly shorter than that of those with a small BTS (median; 2.07 [95% confidence interval [CI]=0.99-6.77] months versus 6.39 [95%CI=4.17-11.50] months) (p=0.044). OS of patients with large BTS was also significantly shorter (p
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.13180